Fig. 5.

The biomedical applications of CMNDDs. (A) Survival curves of the surgically treated G422-bearing mice after intravenous administration of saline, the blank NEs (5 × 10⁶ cells/mouse), CL/NEs without PTX (5 × 10⁶ cells/mouse), Taxol (10 mg/kg PTX), PTX-CL (10 mg/kg PTX) and PTX-CL/NEs (5 × 10⁶ cells/mouse, equivalent to 5 mg/kg PTX) (n = 12 mice per group). Arrow indicates the time of the surgery. A is preprinted with the permission from Springer Nature Ref [86]. (B) Schematic diagram of a bilateral tumor model on the back of mouse, and fluorescence images of DiR-labeled NPs rearrangement in vivo under the magnetic field for 48 h photographed by in vivo imaging system. Pink circle, under magnetic field; Blue circle, without magnetic field. B is preprinted with the permission from Springer Nature Ref [128]. (C) Representative in vivo imaging images of brain and spinal cord displaying DiR 750 signal 2 day and 5 days after backpack-monocyte (BP-Mo) administration. Fluorescence quantification of relative dose accumulated in the CNS (cumulative brain and spinal cord signal); mean ± SD (n = 4). (D) Representative antimyelin basic protein (MBP) staining, revealing areas of demyelination, and hematoxylin and eosin (H&E) staining, revealing inflammatory infiltrates, for lumbar spinal cord sections of mice treated with Saline, Monocytes, and BP-Monocytes (n = 5). Anti-MBP scale bar represents 100 μm. H&E scale bar represents 50 μm. C and D is preprinted with the permission from PNAS Ref [131]. (E) In vivo fluorescence images of IPF mice intravenous injection with MOMC-DiR, MOMC/PER-DiR, and DiR (n = 3) and quantification of the in vivo retention profile (n = 3). E is preprinted with the permission from AAAS Ref [132]